Last deal

$1.8M

Amount

Venture - Series Unknown

Stage

10.07.2013

Date

3

all rounds

$2.55M

Total amount

date founded

Financing round

General

About Company
viDA Therapeutics develops treatments for chronic inflammatory and age-related diseases.

Industry

Sector :

Subsector :

Keywords :

founded date

01.02.2008

Number of employees

Company Type

For Profit

Last funding type

Venture - Series Unknown

IPO status

Private

Description

The Canada-based biotech company is a spin-off from the University of British Columbia and Providence Health Care Research Institute. viDA's biopharmaceutical services focus on researching and developing therapeutics that target granzyme serine proteases, which are responsible for causing inflammation, disruption of barrier function, and vascular leakage. Their treatments aim to improve medical treatment for patients suffering from age-related chronic inflammatory diseases.
Similar Companies
1000
Enleofen Bio Pte Ltd

Enleofen Bio Pte Ltd

Enleofen is a biotech company that develops antibody therapeutics for fibro-inflammatory diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Singapore

total rounds

1
Athersys

Athersys

Athersys is a biotechnology company focused on developing regenerative medicine therapies for various medical conditions.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cleveland, OH, USA

total rounds

9

total raised

$208.9M
Palatin Technologies

Palatin Technologies

Palatin is a biopharmaceutical company developing medicines that target the melanocortin peptide receptor system.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cranbury, NJ, USA

total rounds

9

total raised

$133.9M
Therini Bio

Therini Bio

Therini Bio, Inc. is developing novel therapeutics for neuroinflammatory diseases caused by vascular dysfunction.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

San Francisco, CA, USA

total rounds

6

total raised

$91.97M

Financials

Funding Rounds
3
3

Number of Funding Rounds

$2.55M

Money Raised

Their latest funding was raised on 10.07.2013. Their latest investor BDC Venture Capital. Their latest round Venture - Series Unknown

Date 
Funding Round 
Investors 
Money Raised 
Lead 
BDC Venture Capital

BDC Venture Capital

BDC is a Canadian bank that supports entrepreneurs through financing and consulting.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Keywords

Financial Services, Banking, Finance

Location

Calgary, AB, Canada

count Of Investments

579

count Of Exists

114
BDC Venture Capital

BDC Venture Capital

BDC is a Canadian bank that supports entrepreneurs through financing and consulting.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Keywords

Financial Services, Banking, Finance

Location

Calgary, AB, Canada

count Of Investments

579

count Of Exists

114
Co-Investors
Investors
1
1

Number of lead investors

1

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Venture - Series Unknown
BDC Venture Capital

BDC Venture Capital

BDC is a Canadian bank that supports entrepreneurs through financing and consulting.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Keywords

Financial Services, Banking, Finance

Location

Calgary, AB, Canada

count Of Investments

579

count Of Exists

114

People

Founders
2
David Granville
David Granville

David Granville

David Granville, Ph.D. Co-founder and Scientific Founder of the Company in 2008, David Granville serves as the Company’s Chief Scientific Officer (CSO) and is a Full Professor and Director of the GEM Facility at the Providence Heart + Lung Institute at St. Paul’s Hospital, University of British Columbia (UBC). David Granville completed his Ph.D. at UBC and post-doctoral training at the Scripps Research Institute (La Jolla, CA). He worked in preclinical pharmacology at QLT Inc. from 1994-2000. David Granville was recruited to UBC in 2003 as a Tier II Canada Research Chair and Michael Smith Foundation for Health Research Scholar. Since then, David Granville has received numerous awards for his scholarly and research achievements including a Canada Top 40 Under 40™ award, 2010 Business in Vancouver Forty Under 40 award, 2006 UBC Outstanding Young Alumnus Award, 2007 Simon Fraser University Academic Alumnus Award, 2008 Canadian Academy of Pathology Scientist award and was a finalist for the prestigious 2007 Louis and Arnold Katz Basic Science Prize at the American Heart Association Scientific Sessions.

current job

viDA Therapeutics
viDA Therapeutics

organization founded

1

David Granville

Alistair Duncan
Alistair Duncan

Alistair Duncan

Alistair Duncan, B.Sc., C.A. Co-founder of the Company in 2008 Alistair Duncan serves as President and Chief Executive Officer (CEO) of the Company. From 2009 to present, Alistair Duncan was co-founder, Director, and has served as interim Chief Financial Officer for Agrisoma Biosciences Inc., a company building a high performance crop seeds business for the development of new genetically modified crops for renewable fuels. From 1998 to 2008, Alistair Duncanwas President and CEO of Chromos Molecular Systems Inc., where he was also a co-founder and Director. Prior to that, he was a Principal with the Ernst & Young Corporate Finance and International Life Sciences Group where he provided high technology and life sciences companies with corporate advisory services in strategic planning, valuations, financing, divestitures, and mergers and acquisitions. Currently, Alistair Duncan also serves as a director on the board of Metro Vancouver Properties Corp. Alistair Duncan is a member of the Institute of Chartered Accountants of British Columbia and holds a B.Sc. in Biochemistry from the University of British Columbia.

current job

viDA Therapeutics
viDA Therapeutics

organization founded

2

Alistair Duncan

Employee Profiles
3

Ronald Nardi

SAB Member

David Granville

David Granville

Co-Founder & CSO

Alistair Duncan

Alistair Duncan

Co-Founder, President & CEO

Activity

Recent News
0